- Childhood Acute Illness Trial (CHAIN 2.0/PB-SAM) (2021-2023)
- Kawempe Community Health Study (DMID 01-005; 2002-2017)
- Viti Inc. (2014-2015)
- Gates Grand Challenge (2013-2015)
- AZD 5847 Early Bactericidal Activity (DMID 11-0006; 2012-2015)
- Isoniazid - BCG (DMID 07-0083; 2009-2015)
- Innate Immunity Study (2008-2015)
- Large Scale Antibody and T-cell Epitope Discovery Program (2011-2014)
- Nitazoxanide Antimicrobial Study (2013)
- Infant Predictor Study (2008-2012)
- Gates Grand Challenge (2006-2012)
- Nucleic Acid Amplification Study (DMID 08-0023; 2008-2010)
- Pathway Analysis of Tuberculosis Pathogenesis (2004-2010)
- Doris Duke - TB/HIV Case Finding (2007-2009)
- TB Immunity in Children (2007-2009)
- Induced Immunity (2003-2009)
- Punctuated Antiretroviral Therapy (2002-2009)
- Treatment Shortening (DMID 01-009; 2002-2008)
- Early Bactericidal Activity (DMID 01-553; (1999-2006)
- Immunologic and Microbiologic Predictors (1999-2006)
- IL-2 (Proleukin®) (DMID 98-002; 1999-2002)
- Microbiology Pilot Study (1995-2001)
- Mycobacterium vaccae (DMID 94-120; 1994-2001)
- Household Contact Study (DMID 94-118; 1995-2000)
- KRM-1648 (Rifalazil) (DMID 97-012; 1997-1998)